Necrosulfonamide-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemENecrosulfonamideCat.No.:HY-100573CASNo.:1360614-48-7分?式:C??H??N?O?S?分?量:461.47作?靶點:MixedLineageKinase作?通路:MAPK/ERKPathway儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:≥28mg/mL(60.68mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.1670mL10.8349mL21.6699mL5mM0.4334mL2.1670mL4.3340mL10mM0.2167mL1.0835mL2.1670mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:2.5mg/mL(5.42mM);Suspendedsolution;Needultrasonic2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.5mg/mL(5.42mM);Suspendedsolution;Needultrasonic3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:2.5mg/mL(5.42mM);Suspendedsolution;Needultrasonic4.請依序添加每種溶劑：20%SBE-β-CDinsalineSolubility:6.67mg/mL(14.45mM);Suspendedsolution;Needultrasonic5.請依序添加每種溶劑：50%PEG300>>50%salineSolubility:10mg/mL(21.67mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Necrosulfonamide，?種necroptosis抑制劑，通過選擇性靶向(MLKL)。Necrosulfonamide阻?MLKL-RIP1-RIP3壞死?體復(fù)合體與其下游效應(yīng)?相互作?。MLKL誘導(dǎo)壞死過程中RIP3的重底物。體外研究NecrosulfonamidespecificallyblocksnecrosisdownstreamofRIP3activation.NecrosulfonamideinhibitsMLKL-mediatednecrosisbyblockingItsN-terminalCCdomainfunction[1].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Circulation.2022Nov30.?JClinInvest.2021Nov9;e151268.?NatCommun.2022Nov17;13(1):7031.?Autophagy.2021Jul20;1-19.?JExpClinCancerRes.2021Jun23;40(1):206.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].SunL,etal.Mixedlineagekinasedomain-likeproteinmediatesnecrosissignalingdownstreamofRIP3kinase.Cell.2012;148(1-2):213-227.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuse